203 related articles for article (PubMed ID: 11841415)
21. The C-terminal fragment of axon guidance molecule Slit3 binds heparin and neutralizes heparin's anticoagulant activity.
Condac E; Strachan H; Gutierrez-Sanchez G; Brainard B; Giese C; Heiss C; Johnson D; Azadi P; Bergmann C; Orlando R; Esmon CT; Harenberg J; Moremen K; Wang L
Glycobiology; 2012 Sep; 22(9):1183-92. PubMed ID: 22641771
[TBL] [Abstract][Full Text] [Related]
22. Preparation and evaluation a new generation of low molecular weight heparin.
Zhao D; Sang Q; Cui H
Biomed Pharmacother; 2016 Apr; 79():194-200. PubMed ID: 27044828
[TBL] [Abstract][Full Text] [Related]
23. Does protamine chloride neutralize low molecular weight heparin sufficiently?
Gram J; Mercker S; Bruhn HD
Thromb Res; 1988 Dec; 52(5):353-9. PubMed ID: 2851882
[TBL] [Abstract][Full Text] [Related]
24. Neutralisation of heparan sulphate and low molecular weight heparin by protamine.
Hubbard AR; Jennings CA
Thromb Haemost; 1985 Feb; 53(1):86-9. PubMed ID: 3158095
[TBL] [Abstract][Full Text] [Related]
25. Ultrasonic-assisted preparation of a low molecular weight heparin (LMWH) with anticoagulant activity.
Achour O; Bridiau N; Godhbani A; Le Joubioux F; Bordenave Juchereau S; Sannier F; Piot JM; Fruitier Arnaudin I; Maugard T
Carbohydr Polym; 2013 Sep; 97(2):684-9. PubMed ID: 23911501
[TBL] [Abstract][Full Text] [Related]
26. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
[TBL] [Abstract][Full Text] [Related]
27. Strategies for improving the functionality of an affinity bioreactor.
Wang T; Yang Z; Emregul E; David A; Balthasar JP; Liang J; Yang VC
Int J Pharm; 2005 Dec; 306(1-2):132-41. PubMed ID: 16246511
[TBL] [Abstract][Full Text] [Related]
28. Low molecular weight protamine: a potent but nontoxic antagonist to heparin/low molecular weight protamine.
Byun Y; Chang LC; Lee LM; Han IS; Singh VK; Yang VC
ASAIO J; 2000; 46(4):435-9. PubMed ID: 10926141
[TBL] [Abstract][Full Text] [Related]
29. Dextran sulfate included in factor Xa assay reagent overestimates heparin activity in patients after heparin reversal by protamine.
Mouton C; Calderon J; Janvier G; Vergnes MC
Thromb Res; 2003; 111(4-5):273-9. PubMed ID: 14693175
[TBL] [Abstract][Full Text] [Related]
30. Management of an unintentional enoxaparin overdose: A case report and literature review.
Zhou FN; Gellatly RM
Am J Health Syst Pharm; 2023 Oct; 80(21):1550-1556. PubMed ID: 37522871
[TBL] [Abstract][Full Text] [Related]
31. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Hirsh J; Raschke R
Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
[TBL] [Abstract][Full Text] [Related]
32. Neutralization of the anticoagulant activity of low molecular weight heparin LU 47311 (Clivarin) in man by protamine chloride.
Andrassy K; Eschenfelder V; Weber E
Thromb Res; 1994 Jan; 73(2):85-93. PubMed ID: 8171416
[TBL] [Abstract][Full Text] [Related]
33. Identification of a heparosan heptasaccharide as an effective anti-inflammatory agent by partial desulfation of low molecular weight heparin.
Pan Q; Zhang C; Wu X; Chen Y
Carbohydr Polym; 2020 Jan; 227():115312. PubMed ID: 31590876
[TBL] [Abstract][Full Text] [Related]
34. The design and synthesis of new synthetic low-molecular-weight heparins.
Chandarajoti K; Liu J; Pawlinski R
J Thromb Haemost; 2016 Jun; 14(6):1135-45. PubMed ID: 26990516
[TBL] [Abstract][Full Text] [Related]
35. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins.
Harenberg J; Siegele M; Dempfle CE; Stehle G; Heene DL
Thromb Haemost; 1993 Dec; 70(6):942-5. PubMed ID: 8165616
[TBL] [Abstract][Full Text] [Related]
36. Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors.
Lindblad B; Borgström A; Wakefield TW; Whitehouse WM; Stanley JC
Thromb Res; 1987 Oct; 48(1):31-40. PubMed ID: 2827339
[TBL] [Abstract][Full Text] [Related]
37. Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
Andrassy K
Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S39-43. PubMed ID: 8180328
[TBL] [Abstract][Full Text] [Related]
38. Intentional overdose with tinzaparin: management dilemmas.
Balla I; Karafotias I; Christopoulos C
J Emerg Med; 2014 Feb; 46(2):197-201. PubMed ID: 24084058
[TBL] [Abstract][Full Text] [Related]
39. Effective and less toxic reversal of low-molecular weight heparin anticoagulation by a designer variant of protamine.
Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Schmidt R; Tejwani S; Stanley JC
J Vasc Surg; 1995 May; 21(5):839-49; discussion 849-50. PubMed ID: 7769743
[TBL] [Abstract][Full Text] [Related]
40. Neutralizing the anticoagulant activity of ultra-low-molecular-weight heparins using N-acetylglucosamine 6-sulfatase.
Zhou X; Li L; Linhardt RJ; Liu J
FEBS J; 2013 May; 280(10):2523-32. PubMed ID: 23374371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
